ZILUCOPLAN SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for zilucoplan sodium and what is the scope of freedom to operate?
Zilucoplan sodium
is the generic ingredient in one branded drug marketed by Ucb Inc and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.Zilucoplan sodium has one hundred and thirty-four patent family members in thirty countries.
One supplier is listed for this compound.
Summary for ZILUCOPLAN SODIUM
| International Patents: | 134 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | ZILUCOPLAN SODIUM at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZILUCOPLAN SODIUM
Generic Entry Date for ZILUCOPLAN SODIUM*:
Constraining patent/regulatory exclusivity:
TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN ADULT PATIENTS WHO ARE ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ZILUCOPLAN SODIUM
| Drug Class | Complement Inhibitor |
| Mechanism of Action | Complement Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ZILUCOPLAN SODIUM
US Patents and Regulatory Information for ZILUCOPLAN SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-002 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-002 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-002 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-003 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-003 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZILUCOPLAN SODIUM
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 3389692 | ⤷ Sign Up | |
| Singapore | 11201610222U | MODULATION OF COMPLEMENT ACTIVITY | ⤷ Sign Up |
| China | 111187338 | 补体活性的调节 (MODULATION OF COMPLEMENT ACTIVITY) | ⤷ Sign Up |
| South Korea | 102503319 | ⤷ Sign Up | |
| Cyprus | 1124761 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZILUCOPLAN SODIUM
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3154561 | 301275 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ZILUCOPLAN; REGISTRATION NO/DATE: EU/1/23/1764 20231204 |
| 3154561 | 17/2024 | Austria | ⤷ Sign Up | PRODUCT NAME: ZILUCOPLAN; REGISTRATION NO/DATE: EU/1/23/1764 (MITTEILUNG) 20231204 |
| 3154561 | PA2024514 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ZILUKOPLANAS; REGISTRATION NO/DATE: EU/1/23/1764 20231201 |
| 3154561 | LUC00343 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: ZILUCOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1764 20231204 |
| 3154561 | 2024C/518 | Belgium | ⤷ Sign Up | PRODUCT NAME: ZILUCOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1764 20231204 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
